Terlipressin plus albumin infusion:: an effective and safe therapy of hepatorenal syndrome
Terlipressin plus albumin infusion:: an effective and safe therapy of hepatorenal syndrome
复制标题
DOI：
10.1016/s0168-8278(00)80158-0
复制
发表时间：
2000-07-01
影响因子：
25.7
通讯作者：
Rodés, J
中科院分区：
文献类型：
--
作者：
Uriz, J;Ginès, P;Rodés, J
背景/目的：奥尼加压素是一种具有强效内脏血管收缩作用的加压素类似物，已被证明可逆转肝肾综合征。然而，其在临床实践中的实用性受到频繁的缺血性并发症的限制，本研究的目的是评估特利加压素的疗效，特利加压素是一种副作用低的加压素类似物，加上白蛋白在这种情况下。方法：9例肝硬化和肝肾综合征患者被纳入特利加压素的初步研究结果：治疗（9天，范围5-15）与血清肌酐（3.9+/-0.7至1.3+/-0.1 mg/dl，p < 0.05）显著降低相关。
Background/Aim: Ornipressin, a vasopressin analog with potent splanchnic vasoconstrictor action, has been shown to reverse hepatorenal syndrome. However, its usefulness in clinical practice is limited by frequent ischemic complications, The aim of this study was to assess the efficacy of terlipressin, an analog of vasopressin with a low profile of side effects, plus albumin in this condition.Methods: Nine consecutive patients with cirrhosis and hepatorenal syndrome were included in a pilot study of terlipressin (0.5-2 mg/4 h iv) therapy associated with iv albumin.Results: Treatment (9 days, range 5-15) was associated with a marked reduction of serum creatinine (3.9+/-0.7 to 1.3+/-0.1 mg/dl, p